

Morgan Welch Inflammatory Breast Cancer Research Program  
Lite Bites / High Tea Wednesday, October 4, 2017  
Honoring IBC Patients, Advocates, Volunteers,  
and IBC Ambassadors



*Photo Courtesy: MD Anderson Medical Graphics & Photography*

The Lite Bites / High Tea Honoring IBC Patients, Advocates, Volunteers, and the IBC Ambassadors was held Wednesday, October 4, 2017. The event was put together by the Morgan Welch Inflammatory Breast Cancer Research Program team and volunteers. The Tea Ceremony was a huge success. We would like to extend a special thank you to all the volunteers that took the time out of their busy lives to support and help the IBC program. The food, music, décor, and entertainment provided a great atmosphere for our invited guest.

We wish to share the great news that Congressman Darrell Issa, from the great state of California read a statement into the National Congressional Record in Washington DC. This reading was to show the importance of how inflammatory breast cancer should be discussed in communities, in education, and in research, and to bring national attention to the disease. He declared October 4<sup>th</sup> National Inflammatory Breast Cancer day.





Thank you to the JNDD string Quartet for providing such beautiful music for all of us to enjoy.

JNDD String Quartet members: Jie Willey (Violin), David Wang (Violin), Newman Liu (Viola) and David Gong (Cello). Special guest ShuHong Lin (Violin).



A formal tea tasting and ink art demonstration was provided by Houston artist Mrs. Weighong.

Guests not only observed the Chinese traditional tea culture ceremony, but tasted a delicious variety of tea from China, and learned good health habits.



WeiHong's art has mirrored the Asian cultural diaspora ranging from expected yin/yang concepts to more intuitive notions of chi, Taoism, and Zen Buddhism.

She is an internationally exhibited painter and an installation and performance artist.



Her solo exhibitions include cities in China, Italy, France, Mexico, the Netherlands, and the US.

Her art projects involve line, form, flow, yin and yang with elegantly conceived and perfectly enacted fusion of East/West visual vocabularies.

We extend our appreciation to Mrs. Terry Arnold of the IBC Network, and her friend Jane. Both ladies provided the flower decorations and décor. The Tea Ceremony would not have been made possible without her expertise and tireless efforts in helping prepare and set-up the conference room.





## Recent Awards and Grants

We congratulate the following individuals who have been recognized for their significant accomplishments in IBC research:

**Bisrat G. Debeb, DVM, Ph.D.**, Assistant Professor, received the Susan G. Komen Jon Shevel Youngest Scientist Travel Scholarship Award in the amount of \$1,500.

**Jihyun Park, Ph.D.**, Postdoctoral Fellow, was selected as an Oral Competition finalist to present at the Trainee Research Day 2017. Nearly 100 eligible abstracts were received in four categories, hers was the Basic Science category.

**Bora Lim, MD**, Assistant Professor, was selected to submit her Grant titled “Defining Cell Types and States in Inflammatory Breast Cancer” to the SWOG/ITSC pilot program.

### THE 6<sup>TH</sup> ANNUAL ZETA TAU ALPHA HOUSTON ALUMNAE ASSOCIATION FELLOWSHIP AWARD IN INFLAMMATORY BREAST CANCER RESEARCH

*Awarded To*



**Xiaotong Li, Ph.D.**  
**Candidate, Computational  
Biology & Bioinformatics,  
Biological & Biomedical  
Sciences, Yale University**

**Abstract:** Landscape of somatic mutations in inflammatory breast cancer whole-genome sequences

**Authors:** Xiaotong Li, Savitri Krishnamurthy, Sushant Kumar, Arif Harmonic, Shantao Li, Robert Kitchen, Vikram B. Wali, Yang Zhang, Sangeetha Reddy, Wendy Woodward, James Reuben, Jeffery Chuang, Christos Hatzis, Naoto T. Ueno, Mark Gerstein, Lajos Pusztai



**Nicholaus Trenton, Ph.D.**  
**Candidate, Diehl  
Laboratory, Department  
of Bioengineering, Rice  
University**

**Abstract:** DNA-based nanoparticle multiplexed imaging to study the inflammatory breast cancer cell microenvironment

**Authors:** Nicholaus J Trenton, Khoi Chu, Adam R Wolfe, Walter N Hittelman, Wendy A Woodward, Michael R Diehl

## Recent Publications

**Improved Locoregional Control in a Contemporary Cohort of Nonmetastatic Inflammatory Breast Cancer Patients undergoing Surgery.** [Ann Surg Oncol](#). 2017 Aug 1. doi: 10.1245/s10434-017-5952-x.

Rosso KJ, Tadros AB, Weiss A, Warneke CL, DeSnyder S, Kuerer H, Ueno NT, Stecklein SR, Woodward WA, Lucci A

## **EGFR signaling promotes inflammation and cancer stem-like activity in inflammatory breast cancer**

[Oncotarget](#). 2017; 8:67904-67917. <https://doi.org/10.18632/oncotarget.18958>.

Wang X, Reyes M, Zhang D, Funakoshi Y, Trape AP, Gong Y, Kogawa T, Eckhardt BL, Masuda H, Pirman Jr DA, Yang PY, Reuben JM, Woodward WA, Bartholomeusz C, Hortobagyi GN, Tripathy D, Ueno NT

## **Discovery of a potent inhibitor of MELK that inhibits expression of the anti-apoptotic protein Mcl-1 and TNBC cell growth** [Bioorg Med Chem](#). 2017 May 1;25(9):2609-2616. doi: 10.1016/j.bmc.2017.03.018. Epub 2017 Mar 10.

Edupuganti R, Taliaferro JM, Wang Q, Xie X, Cho EJ, Vidhu F, Ren P, Anslyn EV, Bartholomeusz C, Dalby KN

## **Inflammatory Breast Cancer: a model for investigating cluster-based dissemination** [NPJ Breast Cancer](#). 2017 Jun 6;3:21. doi: 10.1038/s41523-017-0023-9. eCollection 2017.

Jolly MK, Boareto M, Debeb BG, Aceto N, Farach-Carson MC, Woodward WA, Levine H

## **Lack of Breast feeding History in Parous Women with Inflammatory Breast Cancer Predicts Poor Disease-Free Survival** [J Cancer](#). 2017 Jul 1;8(10):1726-1732. doi: 10.7150/jca.20095. eCollection 2017.

Stecklein SR, Reddy JP, Wolfe AR, Lopez MS, Fouad TM, Debeb BG, Ueno NT, Brewster AM, Woodward WA

## **Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer** [Ann Oncol](#). 2017 Oct 1;28(10):2420-2428. doi: 10.1093/annonc/mdx397.

Fujii T, Kogawa T, Dong W, Sahin AA, Moulder S, Litton JK, Tripathy D, Iwamoto T, Hunt KK, Pusztai L, Lim B, Shen Y, Ueno NT

## **MELK: a potential novel therapeutic target for TNBC and other aggressive malignancies** [Expert Opin Ther Targets](#). 2017 Sep;21(9):849-859. doi: 10.1080/14728222.2017.1363183. Epub 2017 Aug 16.

Pitner MK, Taliaferro JM, Dalby KN, Bartholomeusz C

## **Reverse phase protein array identification of triple-negative breast cancer subtypes and comparison with mRNA molecular subtypes** [Oncotarget](#). 2017; 8:70481-70495. <https://doi.org/10.18632/oncotarget.19719>.

Masuda H, Qi Y, Liu S, Hayashi N, Kogawa T, Hortobagyi GN, Tripathy D, Ueno NT

## **Prospective Feasibility Trial of Sentinel Lymph Node Biopsy in the Setting of Inflammatory Breast Cancer** [Clin Breast Cancer](#). 2017 Jul 10. pii: S1526-8209(17)30366-X. doi: 10.1016/j.clbc.2017.06.014.

DeSnyder SM, Mittendorf EA, Le-Petross C, Krishnamurthy S, Whitman GJ, Ueno NT, Woodward WA, Kuerer HM, Akay CL, Babiera GV, Yang W, Lucci A

## **Thrombocytosis as a prognostic factor in inflammatory breast cancer** [Breast Cancer Res Treat](#). 2017 Aug 22. doi: 10.1007/s10549-017-4463-6.

Harano K, Kogawa T, Wu J, Yuan Y, Cohen EN, Lim B, Reuben JM, Ueno NT

## **Androgen receptor expression on circulating tumor cells in metastatic breast cancer** [PLoS One](#). 2017 Sep 28;12(9):e0185231. doi: 10.1371/journal.pone.0185231. eCollection 2017.

Fujii T, Reuben JM, Huo L, Espinosa Fernandez JR, Gong Y, Krupa R, Suraneni MV, Graf RP, Lee J, Greene S, Rodriguez A, Dugan L, Louw J, Lim B, Barcenas CH, Marx AN, Tripathy D, Wang Y, Landers M, Dittamore R, Ueno NT

## News/Events

### SAVE THE DATE(S):

# BOOT WALK

to #endcancer®

Register      Donate      Volunteer

Houston Boot Walk  
Saturday, Nov. 11 | 1:00 p.m.  
Texas Medical Center

Help end Breast Cancer please click on the link below. Our team name is "IBC Wranglers." MD Anderson Boot Walk to End Cancer (<https://www.mdanderson.org/bootwalk>).



Fund Raising Tools Now Available – donate using credit card; customize your personal page or just use the standard template that MD Anderson provides; add contacts to the address book; send mass emails out in one submit; send follow-ups; thank you letters.

Morgan Welch Inflammatory Breast Cancer and Breast Medical Oncology will be collaborating together to help bring awareness to Breast Cancer. Stop by and be a part of the team by signing up for the MD Anderson Boot Walk.

- Tuesday, October 17<sup>th</sup> at 11:00 AM – 2:00 PM at Pickens Tower Bridge Foyer
- Wednesday, October 25<sup>th</sup> at 11:00 AM – 2:00 PM at Mays Hub

## Quarterly Oral Presentations

### **Immune and molecular determinants of response to neoadjuvant chemotherapy in inflammatory breast cancer**

*Sangeetha Reddy, MD, MSci  
Hematology-Oncology Fellow  
Division of Cancer Medicine*

### **Wrap up of ongoing IBC targeted clinical trials, and new initiatives in genomic study of IBC**

*Bora Lim, MD  
Assistant Professor  
Breast Medical Oncology*

## **Influence of nursing on inflammatory breast cancer symptoms**

*Wendy Woodward, MD, Ph.D.  
Associate Professor  
Radiation Oncology*

## **Neoadjuvant and adjuvant systemic therapy of HER-2 amplified breast cancer: 2017 Update**

*Vicente Valero, M.D.  
Professor, Deputy Chairman  
Breast Medical Oncology Department*

## **A pre-clinical PDX-derived ex-vivo tumor model – Furthering our understanding of IBC tumorigenesis and identifying new and effective therapies**

*Geoffrey Bartholomeusz, Ph.D.  
Associate Professor  
Department of Experimental Therapeutics*

## **Current Clinical IBC Trials Open for New Patient Enrollment**

### **Neoadjuvant (newly diagnosed):**

2016-0177 – A randomized phase II study of neoadjuvant Carboplatin/Paclitaxel (CT) versus Panitumumab/Carboplatin/Paclitaxel (PaCT) Followed by Anthracycline-containing regimen for newly diagnosed primary triple-negative inflammatory breast cancer

### **Adjuvant (after surgery and radiation):**

2016-0096 – A phase II study of anti-PD1 (Pembrolizumab) in combination with hormonal therapy in patients with hormone-receptor (HR)-positive localized inflammatory breast cancer (IBC) who did not achieve a pathological complete response (pCR) to neoadjuvant chemotherapy

### **Metastatic IBC:**

2013-0007 – A phase II study of Denosumab to define the role of bone related biomarkers in breast cancer metastasis

2014-0464 – A phase II study of BIBF 1120 (Nintedanib) for Patients with HER2 normal metastatic inflammatory breast cancer

2014-0034 – A phase II study using T-VEC as a single agent for inflammatory breast cancer (IBC) or non-IBC patients with inoperable local recurrence

2014-0533 – A phase II study of anti-PD1 (MK-3475) therapy in patients with metastatic inflammatory breast cancer (IBC) or non-IBC triple negative breast cancer (TNBC) who have achieved clinical response or stable disease to prior chemotherapy.

2016-1096 – A Phase I Study of OTS167PO, a MELK inhibitor, to Evaluate Safety, Tolerability and Pharmacokinetics in Patients with Advanced Breast Cancer and Dose-Expansion Study in Patients with Triple Negative Breast Cancer.

2016-0890 – A phase II study of triple combination of Atezolizumab, Cobimetinib and Eribulin (ACE) in patients with chemotherapy resistant metastatic inflammatory breast cancer



## Current Clinical IBC Lab Studies

2006-1072 – IBC Registry

PA12-0097 – Prognostic utility of CTCs assessed by Adnagen Technology and Clinical Outcome of Patients with Stage III Breast Cancer

PA14-0778 – Gene profiles in androgen-receptor-positive CTC in patients with metastatic breast cancer

PA15-0499 – Tissue biomarker study of T-DM1 and/or Pertuzumab resistant or refractory breast cancer

PA15-1026 – Department of Breast Medical Oncology University Blood Bio-Repositories

PA16-0507 – Monitoring of CTCs in newly diagnosed metastatic breast cancer

PA17-0437 – Genomic profiling of therapy resistance in mTNBC using liquid biopsies

PA17-0503 – Breast tissue comparison - cancer vs normal

If you are interested in learning more about our clinical trials, or lab studies, please email the Morgan Welch Inflammatory Breast Cancer Research Program and Clinic directly at [ibcp@mdanderson.org](mailto:ibcp@mdanderson.org).

Issue 12: October 2017

We are happy to provide general information and eligibility guidelines for our clinical trials and lab studies.

Find us on



THE UNIVERSITY OF TEXAS  
MDAnderson  
~~Cancer~~ Center  
Making Cancer History®